Doubts cast over GSK's $720 million sirtuin gamble
This article was originally published in Scrip
Executive Summary
An increasing body of evidence is suggesting that GlaxoSmithKline's portfolio of sirtuin 1 (SIRT1) activators, which it gained through its $720 million acquisition of Sirtris, do not do what they are supposed to.